CAJ | 학술논문

目的:探讨替吉奥联合伊立替康在结直肠癌化疗中的疗效及安全性.方法:将64例结直肠癌患者随机分为两组,研究组31例,使用替吉奥联合伊立替康,对照组33例,采用FOLFIRI方案.结果:入组病例均可进行疗效评价.研究组完全缓解率(CR)12.9%,部分缓解率(PR)51.6%,有效率(RR)64.5%,对照组完全缓解率(CR)6.1%,部分缓解率(PR)39.4%,有效率(RR)45.5%.研究组有效率高于对照组,但差异无统计学意义(P>0.05).不良反应:两组白细胞减少、腹泻、恶心呕吐、肝功能异常方面差异有统计学意义(P<0.05),而在贫血、血小板减少、肾功能异常、口腔炎、周围神经损伤、手足综合征方面,两组比较差异无统计学意义(P>0.05).研究组及对照组中位无进展期为6.6个月、4.3个月,两组比较差异有统计学意义(P<0.05).结论:替吉奥联合伊立替康治疗结直肠癌疗效肯定,不良反应少,耐受性好.
목적:탐토체길오연합이립체강재결직장암화료중적료효급안전성.방법:장64례결직장암환자수궤분위량조,연구조31례,사용체길오연합이립체강,대조조33례,채용FOLFIRI방안.결과:입조병례균가진행료효평개.연구조완전완해솔(CR)12.9%,부분완해솔(PR)51.6%,유효솔(RR)64.5%,대조조완전완해솔(CR)6.1%,부분완해솔(PR)39.4%,유효솔(RR)45.5%.연구조유효솔고우대조조,단차이무통계학의의(P>0.05).불량반응:량조백세포감소、복사、악심구토、간공능이상방면차이유통계학의의(P<0.05),이재빈혈、혈소판감소、신공능이상、구강염、주위신경손상、수족종합정방면,량조비교차이무통계학의의(P>0.05).연구조급대조조중위무진전기위6.6개월、4.3개월,량조비교차이유통계학의의(P<0.05).결론:체길오연합이립체강치료결직장암료효긍정,불량반응소,내수성호.
@@@@Objective:To investigate the efficacy and safety of S-1 combined with irinotecan for patients with advanced colorectal carcinoma. Method:64 patients with advanced colorectal cancer were randomly divided into two groups.The treatment group was administrated with S-1 combined irinotecan; The control group was administrated with program FOLFIRI.Result:The effective rate was 64.5%,with 4 cases (12.9%)CR, 51.6% PR, 83.9% DCR in thetreatment group ,and The effective rate was 45.5%, with 2 cases(6.1%) CR, 39.4% PR, DCR 72.7% in control group.Adverse reaction:leucopenia,diarrhea,nausea and vomiting,liver function abnormal aspects,significant difference was statistically significant(P<0.05), but in anemia, thrombocytopenia, and renal abnormalities,stomatitis, peripheral nerve injury, brothers syndrome,there was no significant difference between the two groups meaning(P>0.05).The treatment group and control group in which the median progression-free period was 6.6 months and 4.3 months,two groups of comparisons difference had statistical significance(P<0.05).Conclusion:S-1 combined rinotecan in the treatment of advanced colorectal cancer is effective and has mild side effects.It’s tolerance is well.